A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
NCT05481411
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
Olpasiran
Sponsor
Amgen